Krystal Biotech reported its 2019 financial results, highlighting the commencement of the pivotal study for B-VEC and the anticipation of interim Phase 1/2 clinical results for KB105 in the first half of 2020. The company also broke ground on its second cGMP manufacturing facility, ASTRA, and strengthened its senior management team.